Company profile for PolyActiva

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

PolyActiva’s platform technology is used to deliver drugs to specific sites in the body with control over the rate of drug delivery for up to 12-months. The technology involves formation of a polymeric prodrug of the target drug, which in turn is the sole component used to produce the administered product. The product administered to the site can take various forms, including rod-shaped implants, injectable gels, and topical...
PolyActiva’s platform technology is used to deliver drugs to specific sites in the body with control over the rate of drug delivery for up to 12-months. The technology involves formation of a polymeric prodrug of the target drug, which in turn is the sole component used to produce the administered product. The product administered to the site can take various forms, including rod-shaped implants, injectable gels, and topical film. The company began operation in February 2010 and since its formation has secured in excess of $26 million of investment.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Australia
Address
Address
Pty Ltd Level 2, 369 Royal Parade Parkville VIC 3000 Australia
Telephone
Telephone
+61 3 9020 3560
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251105185248/en/PolyActiva-and-RareSight-Form-Strategic-Collaboration-to-Develop-Breakthrough-Treatments-for-Rare-Pediatric-Retinal-Diseases

BUSINESSWIRE
05 Nov 2025

https://www.businesswire.com/news/home/20251015057699/en/PolyActiva-to-Present-Advancements-in-Next-Generation-Ocular-Micro-Implant-Technology-at-Eyecelerator-AAO-2025

BUSINESSWIRE
15 Oct 2025

https://www.businesswire.com/news/home/20250806585386/en/PolyActiva-Announces-First-Patient-Enrolled-in-US-Phase-2b-Clinical-Trial-of-its-Ocular-Micro-Implant-for-Glaucoma-and-Ocular-Hypertension

BUSINESSWIRE
06 Aug 2025

https://www.businesswire.com/news/home/20250716396314/en/PolyActiva-Expands-Executive-Team-to-Drive-Transformational-Growth-and-Advance-Late-Stage-Clinical-Development-in-the-U.S.

BUSINESSWIRE
16 Jul 2025

https://www.businesswire.com/news/home/20250618983729/en/PolyActiva-Appoints-Jerry-St.-Peter-as-CEO-and-Secures-%2425M-Series-C-Financing-to-Accelerate-US-Expansion-and-Clinical-Advancement-of-PREZIA-Technology-Platform

BUSINESSWIRE
18 Jun 2025

https://www.prnewswire.com/news-releases/polyactiva-reports-promising-clinical-trial-results-for-its-6-month-sustained-drug-delivery-biodegradable-ocular-implant-in-glaucoma-patients-301976509.html

PR NEWSWIRE
02 Nov 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty